Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology · 2015 · 873 citations

Medicine, Pharmacokinetics, Pharmacology +16

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Waqqas Afif, Edward V. Loftus, William A. Faubion et al. · The American Journal of Gastroenterology · 2010 · 487 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen et al. · Gut · 2013 · 454 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

Herma H. Fidder, Fabian Schnitzler, Marc Ferrante et al. · Gut · 2008 · 448 citations

Veterinary Medicine, Immunology, Pharmacotherapy +11

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D’Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy.

Gert Van Assche, Geert D’Haens, Maja Noman et al. · Gastroenterology · 2003 · 446 citations

Medicine, Pharmacology, Pharmacotherapy +14